Jose Cabrera
Medical College of Wisconsin
14 Papers
34 Citations
Jose Cabrera is an academic researcher from Medical College of Wisconsin. The author has contributed to research in topics: Inflammatory bowel disease & Medicine. The author has an hindex of 7, co-authored 12 publications. Previous affiliations of Jose Cabrera include Children's Hospital of Wisconsin.
Chat about Author
Papers
Paneth cell defects in Crohn’s disease patients promote dysbiosis
Ta-Chiang Liu,Bhaskar Gurram,Megan T. Baldridge,Richard D. Head,Vy Lam,Chengwei Luo,Yumei Cao,Pippa Simpson,Michael Hayward,Mary L. Holtz,Pavlos Bousounis,Joshua D. Noe,Diana G. Lerner,Jose Cabrera,Vincent Biank,Michael C. Stephens,Curtis Huttenhower,Curtis Huttenhower,Dermot P.B. McGovern,Ramnik J. Xavier,Ramnik J. Xavier,Thaddeus S. Stappenbeck,Nita H. Salzman +22 more
TL;DR: Paneth cell abnormalities in human subjects are associated with mucosal dysbiosis in the context of Crohn's disease, and these changes are related with alterations in oxidative phosphorylation, potentially in a feedback loop.
Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease.
Victoria Grossi,Trudy Lerer,Anne M. Griffiths,Neal S. Leleiko,Jose Cabrera,Anthony R. Otley,James Rick,David R. Mack,Athos Bousvaros,Joel R. Rosh,Andrew B. Grossman,Shehzaad Saeed,Marsha Kay,Brendan M. Boyle,Maria Oliva-Hemker,David J. Keljo,Marian Pfefferkorn,William A. Faubion,Michael D. Kappelman,Boris Sudel,James Markowitz,Jeffrey S. Hyams +21 more
TL;DR: In children with Crohn's disease, concomitant treatment with an immunomodulator for more than 6 months after starting inflIXimab therapy increases the chances that patients will remain on infliximab.
95
Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn's disease.
Whitney M. Sunseri,Jeffrey S. Hyams,Trudy Lerer,David R. Mack,Anne M. Griffiths,Anthony Otley,Joel R. Rosh,Ryan Carvalho,Andrew B. Grossman,Jose Cabrera,Marian Pfefferkorn,James Rick,Neal S. Leleiko,Meredith C. Hitch,Maria Oliva-Hemker,Shehzad Ahmed Saeed,Michael D. Kappelman,James Markowitz,David J. Keljo +18 more
TL;DR: Methotrexate provided sustained clinical remission in nearly one-third of patients with minimal toxicity, and use as first choice IMM is increasing in pediatric CD.
39
Liver enzyme elevations within 3 months of diagnosis of inflammatory bowel disease and likelihood of liver disease.
Alka Goyal,Jeffery S. Hyams,Trudy Lerer,Neal S. Leleiko,Anthony Otley,Anne M. Griffiths,Joel R. Rosh,Jose Cabrera,Maria Oliva-Hemker,David R. Mack,James Rick,Marian Pfefferkorn,Ryan Carvalho,Andrew B. Grossman,Meredith C. Hitch,Boris Sudel,Michael D. Kappelman,Shehzad Ahmed Saeed,William A. Faubion,Marc Schaefer,James Markowitz,David J. Keljo +21 more
TL;DR: Elevation of both alanine aminotransferase (ALT) and GGT within 90 days after the diagnosis of IBD is associated with a markedly increased likelihood of I BD-LD.
21
Medical and Surgical Management of Pediatric Ulcerative Colitis.
Jose Cabrera,Thomas T. Sato +1 more
TL;DR: An overview of IBD occurring during childhood and adolescence has several unique clinical characteristics and surgical management issues and this article provides an overview contrasting these important differences.